<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04832789</url>
  </required_header>
  <id_info>
    <org_study_id>ULTIMATE</org_study_id>
    <nct_id>NCT04832789</nct_id>
  </id_info>
  <brief_title>Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO</brief_title>
  <acronym>ULTIMATE</acronym>
  <official_title>Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO (ULTIMATE) Pilot Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Research Question for the Full ULTIMATE Randomized Clinical Trial (RCT): What is the&#xD;
      effect of ultra-protective ventilation facilitated by extracorporeal membrane oxygenation&#xD;
      (ECMO) versus best current conventional ventilation (CV) on all-cause hospital mortality&#xD;
      among patients with early moderate-severe acute respiratory distress syndrome (ARDS)?&#xD;
&#xD;
      Secondary Research Questions: Among patients with early moderate-severe ARDS, what is the&#xD;
      effect of ultra-protective ventilation versus CV on: (1) duration of mechanical ventilation;&#xD;
      (2) duration of ICU and hospital stay; (3) organ dysfunction; (4) barotrauma; and (5)&#xD;
      mortality at other time-points (ICU discharge, 28-day, 60-day)?&#xD;
&#xD;
      The ULTIMATE Pilot Study: Before embarking on a definitive multinational trial to address the&#xD;
      questions listed above, the ULTIMATE Pilot Study has these 3 specific feasibility objectives:&#xD;
&#xD;
        1. To assess adherence to our explicit mechanical ventilation protocols, with particular&#xD;
           focus on delivered tidal volumes in both groups;&#xD;
&#xD;
        2. To estimate the rate of patient recruitment and understand barriers to recruitment; and&#xD;
&#xD;
        3. To measure and understand the reasons for crossovers or rescue by ECMO in the control&#xD;
           group.&#xD;
&#xD;
      In addition, we will monitor safety issues, recording serious adverse events in both groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients adhering to the study protocol</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Adherence to our explicit ventilation protocols will be adequate if more than 80% of patients have fewer than 10% of monitored values as major protocol violations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients crossing over to VV ECMO</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>The number of protocol withdrawals or off-protocol treatment with VV ECMO will be acceptable if fewer than 10% of patients crossover or receive VV ECMO, when not allowed by the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients recruited for the study</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Patient accrual will be adequate if we recruit 72 patients from 12 sites over 1 year of enrolment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Duration of alive and free of invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>ICU and hospital length of stay in survivors and non-survivors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with non-pulmonary organ dysfunction</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Using standard definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with barotrauma</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>New barotrauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>At ICU discharge and 30-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>At 6 months post-randomization</time_frame>
    <description>Health-related quality of life (EQ-5D) via telephone</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>ARDS</condition>
  <arm_group>
    <arm_group_label>Best conventional ventilation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultra-protective ventilation with ECMO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venovenous ECMO</intervention_name>
    <description>Venovenous ECMO</description>
    <arm_group_label>Ultra-protective ventilation with ECMO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Endotracheal mechanical ventilation for ≤ 5 days&#xD;
&#xD;
          3. Early moderate-severe ARDS (Berlin Definition) - all of the following conditions for ≤&#xD;
             48 hours i. PaO2/FiO2 ≤200 with PEEP &gt; 5 cmH2O ii. bilateral opacities not fully&#xD;
             explained by effusions, lobar/lung collapse, or nodules iii. respiratory failure not&#xD;
             fully explained by cardiac failure or fluid overload iv. within one week of a known&#xD;
             insult of new or worsening respiratory symptoms&#xD;
&#xD;
          4. ARDS severity criterion - either 1 of:&#xD;
&#xD;
               1. PaO2/FiO2 ≤ 150 mm Hg, on PEEP ≥ 10 cm H2O and FiO2 ≥ 0.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently receiving any form of ECMO (e.g., venovenous, venoarterial, or hybrid&#xD;
             configuration)&#xD;
&#xD;
          2. Chronic hypercapnic respiratory failure defined as PaCO2 &gt; 60 mmHg in the outpatient&#xD;
             setting&#xD;
&#xD;
          3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not CPAP&#xD;
&#xD;
          4. Actual body weight exceeding 1 kg per centimeter of height&#xD;
&#xD;
          5. Severe hypoxemia with PaO2/FiO2 &lt; 80 mmHg&#xD;
&#xD;
          6. Expected mechanical ventilation duration &lt; 48 hours&#xD;
&#xD;
          7. Treating team is in the process of moving to a palliative mode of care&#xD;
&#xD;
          8. Moribund patient not expected to survive 24 hours despite ongoing life-sustaining&#xD;
             therapies&#xD;
&#xD;
          9. Confirmed diffuse alveolar hemorrhage from vasculitis&#xD;
&#xD;
         10. Contraindications to limited anticoagulation (e.g., active GI bleeding, bleeding&#xD;
             diathesis)&#xD;
&#xD;
         11. Pregnancy - due to unknown effects of PaCO2 changes on placental blood flow&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niall Ferguson, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eddy Fan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen Exconde</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>5519</phone_ext>
    <email>kathleen.exconde@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Brodie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OHSU Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Terri Hough, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Sean Bagshaw, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Karen Bosma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dave Nagpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Seely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Laveena Munshi, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Kathleen Exconde</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>5519</phone_ext>
      <email>kathleen.exconde@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Shaf Keshavjee, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcelo Cypel, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorenzo Del Sorbo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ewan Goligher, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Neill Adhikari, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unity Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Brochard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Friedrich, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network - Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Elizabeth Wilcox, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>TBA</last_name>
    </contact>
    <investigator>
      <last_name>Francois Lamotagne, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Toronto</investigator_affiliation>
    <investigator_full_name>Eddy Fan</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>Mechanical Ventilation</keyword>
  <keyword>Ventilator-induced lung injury</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

